NEW YORK, May 15 – Myriad Genetics has received eight foreign patents covering the BRCA1 and BRCA2 breast and ovarian cancer genes and their use in the development of therapeutic and predictive medicine products, the company announced on Tuesday.

The European patent is for “Method for Diagnosing a Predisposition for Breast and Ovarian Cancer” using the BRCA1 and 2 genes. Four Canadian patents, two Australian, and one New Zealand patent cover the BRCA genes. Nine patents had already been issued in the United States, according to the company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.